Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Bullous/Blistering Skin Disorders
How do you manage pemphigus vulgaris in patients who lack insurance coverage for biologics and routine laboratory monitoring?
Related Questions
How have you applied the findings of this trial to your current approach to prescribing rituximab for pemphigus patients?
How do you tailor rituximab dosing for mucosal-predominant vs mucocutaneous pemphigus?
Do you change your approach to prednisone taper based on rituximab dosing regimen when treating patients with pemphigus?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?
Are there patients with pemphigus whom you plan to give additional doses of rituximab even if they are in complete remission at six months from their initial dose?
What is your approach to tapering off rituximab in a patient with pemphigus who seems to be remission?
How do you counsel patients with pemhigus on the main safety benefits of a low or ultra low dose rituximab regimen?
How do you manage pemphigus patients who have persistent disease and circulating autoantibodies despite two full courses of rituximab?
Are there subgroups of patients with pemphigus in whom you prioritize lower-dose rituximab regimens?
Should nivolumab be discontinued in a patient who develops bullous pemphigoid but is otherwise responding well to therapy, if BP is being managed with dupilumab?
